Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Efficacy and safety of once-monthly continuous erythropoietin receptor activator in patients with chronic renal anemia.

Locatelli F, Mandolfo S, Menegato Adorati M, Villa G, Tarchini R, Pizzarelli F, Conte F, Guastoni C, Ricciardi B, Crotta A.

J Nephrol. 2013 Nov-Dec;26(6):1114-21. doi: 10.5301/jn.5000251. Epub 2013 Sep 13.

PMID:
24052462
2.

C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.

Bastos K, Lucarelli LA, De Francesco-Daher E, Filho RP, Henríquez C, Espinoza B, Villanueva I, Schwedt E, Schiavelli R, Correa-Rotter R.

Int Urol Nephrol. 2013 Oct;45(5):1355-64. doi: 10.1007/s11255-012-0272-3. Epub 2012 Sep 19.

3.

C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.

Kessler M, Martínez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, Beyer U.

Hemodial Int. 2010 Apr;14(2):233-9. doi: 10.1111/j.1542-4758.2009.00421.x. Epub 2009 Nov 3.

PMID:
19888948
4.

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, Beyer U; STRIATA Study Investigators.

Nephrol Dial Transplant. 2008 Nov;23(11):3654-61. doi: 10.1093/ndt/gfn320. Epub 2008 Jun 27.

5.

Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators.

Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46. Epub 2007 May 23.

6.

Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.

Agarwal A, Silver MR, Walczyk M, Liu W, Audhya P.

J Am Med Dir Assoc. 2007 Feb;8(2):83-90. Epub 2006 Sep 29.

PMID:
17289537
7.

Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.

Silver MR, Agarwal A, Krause M, Lei L, Stehman-Breen C.

Am J Geriatr Pharmacother. 2008 Jun;6(2):49-60. doi: 10.1016/j.amjopharm.2008.05.002.

PMID:
18675764
8.

A single arm, prospective, open label, multicentre study for evaluation of efficacy and safety of IV CERA for treatment of chronic renal anaemia in dialysis patients not currently treated with ESA.

Nainan GK, Pathak VR, Dalal SS, Saxena S, Mittal D, Raju TR, Gokulnath, Isaac R, Rajapurkar MM, Rana DS, Shah BV, Ray DS, Thiagarajan CM, Jha RM, Kukreja AA, Pophale RR.

J Assoc Physicians India. 2014 Mar;62(3):232-6.

PMID:
25327065
9.

Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.

Sánchez-Escuredo A, Batista F, Cases A, Torregrosa JV.

Transplant Proc. 2015 Jan-Feb;47(1):73-5. doi: 10.1016/j.transproceed.2014.12.006.

PMID:
25645774
10.
11.

Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.

Otsuka T, Sakai Y, Yui S, Sukegawa M, Suzuki A, Mugishima K, Sumi Y, Otsuka Y, Tsuruoka S.

J Nippon Med Sch. 2015;82(1):21-6. doi: 10.1272/jnms.82.21.

12.

Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial.

Campistol JM, Carreño A, Morales JM, Pallardó L, Franco A, Navarro D, Grinyó JM, Montenegro J, Sánchez Fructuoso AI, Romero R, Guirado L, Arias M; TIVOLI Study Group.

Transplantation. 2013 Jan 27;95(2):e6-e10. doi: DOI: 10.1097/TP.0b013e3182782f3a. No abstract available.

PMID:
23325012
13.

An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.

Patel M, Thimons DG, Winston JL, Langholff W, McGowan T.

J Am Med Dir Assoc. 2012 Mar;13(3):244-8. doi: 10.1016/j.jamda.2010.09.009. Epub 2010 Nov 11.

PMID:
21450214
14.

Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients.

Choi JY, Yang CW, Kim YH, Joo KW, Yoo TH, Lee KW, Lee SH, Moon JY, Shin SK, Huh W, Kim NH, Park SH, Kim CD, Kim YL.

Kidney Blood Press Res. 2013;37(4-5):259-68. doi: 10.1159/000350151. Epub 2013 Jul 22.

15.

Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.

Roger SD, Kolmakova E, Fung M, Malecki R, Vinhas J, Dellanna F, Thomas M, Manamley N, Ferenczi S.

Nephrology (Carlton). 2014 May;19(5):266-74. doi: 10.1111/nep.12214.

PMID:
24506498
16.
17.

[Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].

Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.

Nefrologia. 2003;23(2):114-24. Spanish.

19.

Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.

Hirai T, Nishizawa Y, Nakazono H, Asai M, Yamashita H, Sasaki A, Yamashita T, Yamashita K, Shigemoto K, Harada S, Mizuiri S.

Ther Apher Dial. 2013 Oct;17(5):498-503. doi: 10.1111/1744-9987.12013. Epub 2013 Feb 28.

PMID:
24107278
20.
Items per page

Supplemental Content

Write to the Help Desk